INTRODUCTION

Rhabdomyolysis is a syndrome caused by the breakdown of skeletal muscle and necrosis resulting from various conditions. The release of intracellular contents and breakdown products into the bloodstream can lead to acute kidney injury (AKI), a life-threatening complication associated with poor outcomes including end-stage renal disease (ESRD) and even death. Trauma patients often endure direct muscle injury; damaged myocytes can release myoglobin, creatine phosphokinase, and lactate dehydrogenase into the circulation, thus creating a heavy burden on the kidneys. Despite extensive research, the mechanisms underlying rhabdomyolysis-induced AKI remain largely elusive. In this study, we established both cell and murine models of rhabdomyolysis-induced AKI by using myoglobin and glycerin, respectively, and provided evidence that protein kinase Cδ (PKC-δ) was activated in both models and subsequently promoted cell apoptosis. Moreover, we found that this detrimental effect of PKC-δ activation can be reversed by its pharmaceutical inhibitor rottlerin. Furthermore, we detected and confirmed the existence of PKC-δ-mediated myoglobin-induced cell apoptosis and the expression of TNF-α and IL1-β via regulation of the p38 MAPK and ERK1/2 signalling pathways. In summary, our research revealed the role of PKC-δ in renal cell apoptosis and suggests that PKC-δ is a viable therapeutic target for rhabdomyolysis-induced AKI.

KEYWORDS
AKI, apoptosis, ERK1/2, p38, PKC-δ
features that cause further damage in the kidney. Exploring the mechanisms underlying renal cell apoptosis might provide us with an interventional method for AKI at an earlier stage.

Protein kinase C is a subgroup of serine/threonine kinases that when activated regulate multiple cellular functions, including cell differentiation, survival and death. Phosphorylated protein kinase C has been reported to influence several renal diseases in manners that both expedite or impede apoptosis; furthermore, isoform-specific inhibitors and agonists have been proven to counter or promote these effects. PKC-δ, one of the key PKC isoforms, is known to play an anti-apoptosis role in tumour cells. However, recent studies showed that PKC-δ promotes renal cell apoptosis under treatments with cisplatin and vancomycin, and in cold storage transplantation-induced AKI.

In the current study, we found that PKC-δ was induced by myoglobin and glycerin both in vitro and in vivo. We also found that the inhibition of PKC-δ by both rottlerin and PKC-δ-KD attenuated the progression of rhabdomyolysis-induced AKI and improved the survival rate. Mechanistically, we used mouse proximal tubular cells to demonstrate that the inhibition of PKC-δ ameliorated myoglobin-induced renal cell apoptosis via the inactivation of the p38MAPK and ERK1/2 pathways. In summary, our data suggested that the inhibition of PKC-δ ameliorates rhabdomyolysis-induced apoptosis in renal epithelial cells and kidney injury.

## METHODS AND MATERIALS

### 2.1 Reagents and antibodies

Antibodies were obtained from the different sources. PKC-δ (2058), phospho-PKC-δ (9374), Caspase3 (9662), cleaved caspase3 (9664), p38 (8690), phospho-p38 (4511) and phospho-p44/42 MAPK (Erk1/2) (4370) were from Cell Signaling Technology (Danvers, MA, USA); anti-Erk1/2 (ab184699) from Abcam (Cambridge, UK); β-Tubulin (T0023) were from affinity (UK); Myoglobin and ascorbic acid were from Sigma-Aldrich (St. Louis, MO, USA). Rottlerin (the inhibitor of PKC) were from Abcam (Cambridge, UK);

### 2.2 Animal model of RM-induced AKI

C57BL/6 mice were purchased from Hunan SJA Laboratory Animal Co., Ltd (Changsha, China). Male C57BL/6 mice aged 8–10 weeks were injected 50% glycerol at a dose of 8ml/kg as previously described; the control group was injected with an equal volume of saline. The mice were injected intraperitoneally with Rottlerin were 10 mg/kg/day to suppress the PKC. Animal experimental protocols were approved by the Care and Use of Laboratory Animals Institutional Committee from Second Xiangya Hospital, China. The mice were housed at stable room temperature in a 12-h light/dark cycle and provided adequate supplies of standard rodent chow and water. We randomly divide twenty mice aged 6–8 weeks into two groups, and mice were intraperitoneally injected with saline or glycerol. We observe the survival of mice within 48 h to obtain the survival curve of mice after injection of glycerol.

### 2.3 Cell culture and treatment

We obtained the BUMPT cell line (mouse renal proximal tubular epithelial cell) from Dr. Wilfred Lieberthal of Boston University School of Medicine. BUMPT cells were cultured with Dulbecco’s modified Eagle’s medium (Gibco) added with 10% foetal bovine serum (Gibco) and 1% penicillin-streptomycin in 5% CO2 at 37 °C. Myoglobin and ascorbic acid were added into the medium for 24 h to establish the RM-induced AKI in vitro as described previously. Cells were plated in 35-mm dish to reach 50%–70% density and then transfected with 1 μg PKC plasmids (PKC-δ-KD, PKC-δ-CF) using Lipofectamin 2000 (Invitrogen) or as previously described. After 6 h of transfection, cells were treated with myoglobin and ascorbic acid. For p38 or ERK1/2 inhibition, BUMPT cells were treated with saline or myoglobin (10mg/ml) for 24 h, with or without p38 MAPK inhibitor (SB203580, 0.5 μM) or ERK1/2 inhibitor (SCH772984, 300 nM) preincubation for 1 h.

### 2.4 Real-time PCR

We use Trizol (Takara, T9108) to extract RNA from tissues and cells according to the instructions and use a reverse transcription kit (Takara, RR037A) to prepare cDNA as previously described, and then, use SYBR green kit (AG, 11701) to detect the following different indicators: TNF-α: forward 5’-TAGCAGGAGGAGAACAG-3’, reverse 5’-TTTCTGGAGGGAGATGTGG-3’; IL-1β: forward 5’-CCCAAGCA TACCAAGAG-3’, reverse 5’-GCTTGTGCTCTGCTTGAG-3’; GADPH: forward 5’-TCGAATGCGTGCTGGAG-3’, reverse 5’-AGTGAGGATTGTGCTGA-3’.

### 2.5 Western blot

We use RIPA Lysis Buffer (Beyotime, P0013C) to extract protein from tissues and cells according to the protocol and perform

---

**FIGURE 1** Glycerine induced renal injury in a time-dependent manner. WT mice were injected intramuscularly with saline or 50% glycerine (8 ml/kg) for 12 or 24 h. (A) Survival rate of WT mice after saline or glycerine treatment for 0h, 24, 36 or 48 h. (B,C) Serum creatinine and BUN measurement. (D,E) Representative images of H&E staining. (F,G) Quantitative analysis of tubular damage. (H) Representative immunoblots of PKC-δ-phosphorylation and Caspase3 activation in whole kidney lysate. (I) Grayscale image analysis between them. Original magnification, ×200. Scale bar, 100 μM. Data are expressed as mean ± SD (n = 6). * p < 0.05 versus Saline group.
experiments by SDS-PAGE, then transfer the protein to the PVDF membrane. Use 5% BSA to block the membrane. After this, incubate the membrane with primary antibody overnight (PKC-δ 1:1000, p-PKC-δ 1:1000, Caspase3 1:1000, cleaved caspase3 1:1000, p38 1:1000, p-p38 1:1000, anti-Erk1/2 1:1000, p-Erk1/2 1:1000, β-Tubulin 1:2000). After washing the membrane with PBS three times, incubate the membrane with second antibody 1 h at room temperature. Finally, we observe the protein band under the instrument (Tanon) through the ECL reagent.

2.6 | TUNEL and HE staining

Tissue is embedded in paraffin and sliced. The sections are deparaffinized and stained differently according to the TUNEL kit (Roche, 11684817910) and HE staining kit as previously described. Histologic changes in the cortex and the outer stripe of the outer medulla (OSOM) were scored by the percentage of renal tubules with loss of brush border, cellular necrosis, cast formation, tubule dilation and vacuolization (0, no damage; 1, <25%; 2, 25%–50%; 3, 50%–75%; 4, >75%). For the analysis of TUNEL, we randomly selected 10–20 fields from each tissue section to count the TUNEL-positive cells per millimetre.

2.7 | Statistics

All data were presented as means ± SD. Two-tailed Student t tests were used for two group comparisons. Two-way ANOVA was used for the multiple group comparisons. p < 0.05 was considered statistically significant.

3 | RESULTS

3.1 | PKC-δ was activated by glycerine-induced AKI

Prior to detecting PKC-δ, we wanted to establish and validate a murine model of rhabdomyolysis-induced AKI. To investigate survival rates, C57BL/6 mice were intramuscularly injected with glycerin at a dose of 14 μl/g for 48 h; resultant data suggested that C57BL/6 mice began to die at 24 h and all mice had died by the 40 h timepoint (Figure 1A). To create a model of AKI, C57BL/6 mice were intramuscularly injected with glycerin a dose of 14 μl/g for 12 and 24 h. Functionally, the levels of serum creatinine and blood urine were notably increased at 12 h and reached a peak at 24 h (Figure 1B,C). H&E staining showed that glycerin induced tubular damage and tube type at 12 h and induced moderate levels of damage by 24 h (Figure 1D); this was supported by the tubular damage score (Figure 1F). TUNEL staining results indicated that glycerine induced renal cell apoptosis at 12 h, and that the levels of apoptosis had increased further by 24 h; this effect was demonstrated by the counting of TUNEL-positive cells (Figure 1E,G). Also, PI staining indicated elevated cell death in a time-dependent manner in mice kidney (Figure S1A,B). Finally, immunoblotting results indicated that glycerine induced the activation of PKC-δ and caspase3 at 12 h; with notable increased levels at 24 h (Figure 1H,I). Further immunoblotting detection showed phosphorylated p38 and ERK1/2 expression were increased too in glycerin-treated mice (Figure S1C,D). We complementarily detected the expression of other PKC-α and PKC-γ and found that they were also activated by glycerin (Figure E,F). Taken together, these data suggested that PKC-δ was activated by glycerine in C57BL/6 mice.

3.2 | Rottlerin attenuated glycerine-induced AKI

To investigate the role of PKC-δ in rhabdomyolysis-induced AKI, rottlerin, a pharmacological inhibitor, was used to suppress the activation of PKC-δ. Firstly, rottlerin notably attenuated glycerine-induced death in C57BL/6 mice (Figure 2A). Secondly, glycerine-induced a decline in renal function; this was ameliorated by rottlerin treatment at 24 h (Figure 2B,C). H&E staining indicated that rottlerin also reduced glycerine-induced renal tubular damage and tube type; this effect was supported by the tubular damage score at 24 h (Figure 2D,F). Thirdly, TUNEL staining results demonstrated that rottlerin also suppressed glycerine-induced renal cell apoptosis at 24 h (Figure 2E,G). Immunoblot results showed that rottlerin markedly attenuated the glycerine-induced activation of PKC-δ and caspase3 at 24 h (Figure 2H,I). We then injected mice with rottlerin after glycerin treatment and found that rottlerin significantly inhibited the activation of phosphorylated p38 and ERK1/2 (Figure S2). In summary, these data suggested that the inhibition of PKC-δ attenuates AKI caused by glycerine.
3.3 | Rottlerin and PKCδ-KD plasmid attenuated renal damage caused by Glycerin and MYO in mice

We then tried to pin the function of PKC-δ in rhabdomyolysis-induced AKI in vivo. We injected the mice with saline or rottlerin (10 mg/kg/day) for three days before they underwent intramuscular glycerin injection. 24 h later, mice kidneys were collected. H&E staining showed markedly decreased tubular damage (Figure S3A,C), and TUNEL staining detected far less apoptosis in mice treated with rottlerin (Figure S3B,D), indicating that inhibition of PKC kinase exerts a renal protective function. To specify the role of PKC-δ, we injected mice with 25 μg PKC-δ-KD plasmid through tail vein per day for three day before intramuscular glycerin injection and found that the activation of PKC-δ p38 MAPK and ERK1/2 were all down-regulated significantly in PKC-δ-KD-treated mice by immunoblotting (Figure S3B,D). These results together confirmed that PKC-δ inhibition can protect kidney from crush syndrome-related renal injury.

3.4 | PKC-δ was activated by myoglobin in BUMPT cells

To further investigate the role of PKC-δ, we used myoglobin in a range of in vitro experiments. Immunoblotting results indicated that myoglobin induced the activation of PKC-δ and caspase3 in a dose-dependent manner (5 and 10 mg/ml) (Figure 3A,B). In addition, myoglobin (10 mg/ml) induced the activation of PKC-δ and caspase3 in a dose-dependent manner (6, 12, and 24 h) (Figure 3C,D). These data showed that myoglobin induced the activation of PKC-δ in BUMPT cells.

3.5 | Rottlerin attenuated myoglobin-induced apoptosis in BUMPT cells

Hoechst staining demonstrated that rottlerin attenuated myoglobin-induced apoptosis in BUMPT cells. This was confirmed by determining the rate of apoptosis (Figure 4A,B). Rottlerin notably attenuated glycine-induced activation of PKC-δ and caspase3 at 24 h (Figure 4C,D). These findings were consistent with the in vivo results.

3.6 | PKC-δ-mediated myoglobin induced BUMPT cell apoptosis and the expression of TNF-α and IL1-β by regulating the p38MAPK and ERK1/2 signalling pathways

Considering the negative effect of rottlerin, we selected PKC-δ-KD as a specific inhibitor of PKC-δ. The transfection rate was detected by immunofluorescence imaging of BUMPT cells transfected with GFP + vector (Figure S4A). Besides, PKC-δ and p-PKC-δ expression in BUMPT cells was down-regulated by PKC-KD transfection and up-regulated by PKC-CF transfection (Figure S4B,C). Immunoblotting results indicated that myoglobin induced the activation of PKC-δ, caspase3, p38MAPK and ERK1/2; this effect was most notable in the PKC-δ-KD treatment (Figure 5A,B). In addition, RT-qPCR analysis demonstrated that PKC-δ-KD markedly suppressed the myoglobin-induced expression of TNF-α and IL1-β (Figure 5C,D). In contrast, these effects were significantly enhanced by the overexpression of PKC-δ-KD (Figure 6). These data suggested that the PKC-δ/
3.7 | P38 MAPK and ERK1/2 inhibitor attenuated MYO-induced BUMPT cell apoptosis

Immunoblotting results indicated that BUMPT cell apoptosis induced by MYO was attenuated after preincubation with p38 or ERK1/2 inhibitor, respectively, while expression of PKC-δ and p-PKC-δ remained unaffected, suggesting PKC-δ influenced renal cell apoptosis via p38MAPK and ERK1/2 pathway(Figure S5).

4 | DISCUSSION

Proximal tubular cell damage is closely associated with AKI. Rhabdomyolysis refers to the breakdown of striated muscle resulting from traumatic events, genetic issues, exertional and non-exertional conditions and can cause renal damage due to the release of cellular contents from damaged muscle cells into the bloodstream; these secretions will eventually poison the kidney. The typical clinical presentation of this condition is pain and weakness in the muscle and the discoloration of urine. Another common factor that is toxic to renal cells is cisplatin. Cisplatin is a common treatment for multiple types of cancers and exerts a
highly toxic effect on the kidneys, thus contributing to renal failure, a severe side effect of chemotherapy. Cisplatin-induced AKI is reported to be facilitated by tubular cell apoptosis and necrosis in both patients and animal models.\textsuperscript{28,29} According to Jianzhong Li et al., metformin may protect against cisplatin-induced renal cell apoptosis by activating AMPK\textsubscript{α}.\textsuperscript{30} Aside from limited advancement in our understanding of the mechanisms that underlie apoptosis in AKI, we know very little about the role of tubular apoptosis in rhabdomyolysis-induced AKI.\textsuperscript{18} In the current study, we initially demonstrated that PKC-δ was induced by glycercin and myoglobin in renal tubular cells and C57BL/6 mice, respectively. Interestingly, the inactivation of PKC-δ by rottlerin markedly reduced glycerine-induced death in C57BL/6 mice and also attenuated the progression of glycerine-induced AKI. Mechanistically, we found that the PKC-δ/p38MAPK and ERK1/2 signalling pathways mediated myoglobin-induced renal cell apoptosis and the expression of TNF-α and IL1-β. These data suggested that the inhibition of PKC-δ has a beneficial effect on AKI induced by rhabdomyolysis.

The function of PKC-δ in apoptosis depends on cell types and stimulating factors.\textsuperscript{26,33-34} In tumour cells, PKC-δ usually antagonizes apoptosis.\textsuperscript{14} In a previous study, we revealed that PKC-δ induced renal cell apoptosis and then led to the progression of nephrotoxicity induced AKI.\textsuperscript{17,18} A more recent study reported that PKC-δ promoted the apoptosis in mitochondria and caused AKI induced by cold storage-associated kidney transplantation.\textsuperscript{35} Consistently, we also found that PKC-δ induced apoptosis in renal tubular cells to promote the progression of rhabdomyolysis-induced AKI. This effect was supported by two lines of evidence. First, rottlerin, a PKC-δ pharmacological inhibitor, attenuated the rhabdomyolysis-induced AKI accompanied by a reduction of renal cell death (Figure 2). Secondly, rottlerin also ameliorated myoglobin-induced renal cell apoptosis (Figure 4). Collectively, these data confirmed that PKC-δ plays an apoptotic role during rhabdomyolysis-induced AKI.

Recent studies suggested that rottlerin non-selectively inhibits PKC-δ and other enzymes, including PKC-α and PKC-η.\textsuperscript{35,36} Therefore, this inhibition experiment alone is insufficient to illustrate the specific function of PKC-δ. To further avoid the non-specific effects of rottlerin, we used PKC-δ-KD and PKC-δ-CF to suppress or overexpress PKC-δ, respectively. Previous studies reported that the P38MAPK and ERK1/2 pathways are related to apoptosis and inflammation.\textsuperscript{37-39} The p38 MAPK (mitogen-activated protein kinase) signalling pathway conducts diverse cell functions by aiding cells to process various signals and is known to participate in cell apoptosis induced by different stimuli.\textsuperscript{40} The ERK1/2 pathway is associated with the inflammatory responses of irritated cells.\textsuperscript{41}
and ERK1/2 signalling pathways (Figure 5). Secondly, PKC-δ-CF enhanced them by activating the p38MAPK and ERK1/2 signalling pathways (Figure 6). These results suggested that the PKC-δ/ p38MAPK and ERK1/2 axis mediated rhabdomyolysis-induced AKI. Still, there are certain deficits in this research. Firstly, we used only inhibitors and plasmids to alter the expression of activated PKC-δ, while more concrete evidence would be presented should specific genomic knockout of PKC-δ in renal tubules was applied. Secondly, we did not investigate the functions of PKCα and PKC-η even though they were also activated in glycerin-induced AKI. What’s more, how glycerin/MYO caused PKC-δ activation is yet to be discovered. Further exploration is required to extend the findings in this study.

In conclusion, our research revealed that PKC-δ mediates rhabdomyolysis-induced AKI via the activation of the P38MAPK and
ERK1/2 pathways (Figure 7), thus providing evidence that PKC-δ is a potent therapeutic target for rhabdomyolysis-induced AKI.

ACKNOWLEDGEMENTS

The study was supported in part by a grant from the National Natural Science Foundation of China [81270475, 81570646, 81770951], the Changsha Science and Technology Bureau Project [kq2001039], the Key Project of Hunan Provincial Science and Technology Innovation [2020SK1014], the Department of Science and Technology of Hunan Province Project of International Cooperation and Exchanges [2020WK2009], the Changsha Science and Technology Bureau Project [kq2014242], the Natural Science Foundation of Hunan Province of China [2021JJ30959] and the Fundamental Research Funds for the Central Universities of Central South University [2020zzts282].

CONFLICT OF INTEREST

The authors have no conflict of interest.

AUTHOR CONTRIBUTION

Dengke Wu: Data curation (lead); Investigation (lead); Validation (lead); Writing – review & editing (equal). Jian Pan: Formal analysis (equal); Methodology (equal); Resources (equal); Visualization (equal); Writing – review & editing (equal). Dongshan Zhang: Conceptualization (lead); Funding acquisition (equal); Writing – original draft (lead); Writing – review & editing (equal).

DATA AVAILABILITY STATEMENT

The data used and/or analyzed are available from the corresponding author by reasonable request.

ORCID

Dongshan Zhang https://orcid.org/0000-0002-7387-4804

REFERENCES

1. Cabral BM, Edding SN, Portocarrero JP, Lerma E.V. Rhabdomyolysis. Dis Mon. 2020;66(8):101015. [published Online First: Epub Date]. 10.1016/j.dismonth.2020.101015
2. Petejova N, Martinek A. Acute kidney injury due to rhabdomyolysis and renal replacement therapy: a critical review. Crit Care. 2014;18(3):224. [published Online First: Epub Date]. 10.1186/cc13897
3. Long B, Koyfman A, Gottlieb M. An evidence-based narrative review of the emergency department evaluation and management of rhabdomyolysis. Am J Emerg Med. 2019;37(3):518-523. [published Online First: Epub Date]. 10.1016/j.ajem.2018.12.061
4. Bagley WH, Yang H, Shah KH. Rhabdomyolysis. Intern Emerg Med. 2007;2(3):210-218. [published Online First: Epub Date]. 10.1007/s11739-007-0060-8
5. Harrois A, Libert N, Duranteau J. Acute kidney injury in trauma patients. Curr Opin Crit Care. 2017;23(6):447-456. [published Online First: Epub Date]. 10.1097/mcco.0000000000000463
6. Messerer DAC, Halbgебauer R, Nilsson B, Ravnentsted H, Rademacher P, Huber-Lang M. Immunopathophysiolo of trauma-related acute kidney injury. Nat Rev Nephrol. 2021;17(2):91-111. [published Online First: Epub Date]. 10.1038/s41581-020-00344-9
7. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35(4):495-516. [published Online First: Epub Date]. 10.1080/01926230701320337
8. Linkermann A, Chen G, Dong G, Kunzendorf U, Krautwald S, Dong Z. Regulated cell death in AKI. J Am Soc Nephrol. 2014;25(12):2689-2701. [published Online First: Epub Date]. 10.1681 ASN.201430262
9. Xu X, Lai Y, Hu ZC. Apoptosis and apoptotic body: disease mechanisms and therapeutic target potentials. Biosci Rep. 2019;39(1). [published Online First: Epub Date]. 10.1042/bsr20180992
10. Priante G, Gianesello L, Ceol M, Del Prete D, Anglani F. Cell death in the kidney. Int J Mol Sci. 2019;20(14):3598. [published Online First: Epub Date]. 10.3390/ijms20143598
11. Isakov N. Protein kinase C (PKC) isozymes in cancer, tumor proliferation and tumor suppression. Semin Cancer Biol. 2018;48:36-52. [published Online First: Epub Date]. 10.1016/j.semcancer.2017.04.012
12. Wang Y, Justilien V, Brennan KJ, Jamieson L, Murray NR, Fields AP. PKCλ regulates nuclear YAP1 localization and ovarian cancer tumorigenesis. Oncogene. 2017;36(4):534-545. [published Online First: Epub Date]. 10.1038/onc.2016.224
13. Altman A, Kong KF. Protein Kinase C Enzymes in the Hematopoietic and Immune Systems. Annu Rev Immunol. 2016;34:511-538. [published Online First: Epub Date]. 10.1146/annurev-immunol-041015-055347
14. Musashi M, Ota S, Shiroshita N. The role of protein kinase C isozymes in cell proliferation and apoptosis. J Cell Mol Med. 2000;72(1):12-19.
15. Li J, Gobe G. Protein kinase C activity and its role in kidney disease. Nephrology. 2006;11(5):428-434. [published Online First: Epub Date]. 10.1096/fj.201801515R
16. Zhang D, Pan J, Xiang X, et al. Protein kinase Cδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer. J Clin Invest. 2011;121(7):2709-2722. [published Online First: Epub Date]. 10.1172/jci45586
17. Zhu J, Zhang G, Song Z, et al. Protein kinase Cδ suppresses autophagy to induce kidney cell apoptosis in cisplatin nephrotoxicity. J Am Soc Nephrol. 2017;28(4):1131-1144. [published Online First: Epub Date]. 10.1681/ASN.2016030337
18. Xu X, Pan J, Li H, et al. Atg7 mediates renal tubular cell apoptosis in vancomycin nephrotoxicity through activation of PKC-δ. Faseb J. 2019;33(3):4513-4524. [published Online First: Epub Date]. 10.1096/fj.201801515R
19. Zhu J, Zhang G, Song Z, et al. Protein kinase C-δ mediates kidney tubular injury in cold storage-associated kidney transplantation. J Am Soc Nephrol. 2020;31(5):1050-1065. [published Online First: Epub Date]. 10.1681/ASN.2019100160
20. Sun T, Liu Q, Wang Y, Deng Y, Zhang D. MDB2 mediates renal cell apoptosis via activation of Tox4 during rhabdomyolysis-induced acute kidney injury. J Cell Mol Med. 2021;25(10):4562-4571. [published Online First: Epub Date]. 10.1111/jcmm.16207
21. Zager RA, Burkhart K. Myoglobin toxicity in proximal human kidney cells: roles of Fe, Ca2+, H2O2, and terminal mitochondrial electron transport. Kidney Int. 1997;51(3):728-738. [published Online First: Epub Date]. 10.1038/ki.1997.104
22. Wang J, Li H, Qiu S, Dong Z, Xiang X, Zhang D. MDB2 upregulates miR-301a-5p to induce kidney cell apoptosis during vancomycin-induced AKI. Cell Death Dis. 2017;8(10):e3120. [published Online First: Epub Date]. 10.1038/cddis.2017.509
23. Wang J, Pan J, Li H, et al. lncRNA ZEB1-AS1 was suppressed by p53 for renal fibrosis in diabetic nephropathy, Mol Ther Nucleic Acids. 2018;12:741-750. [published Online First: Epub Date]. 10.1016/j..omtn.2018.07.012
24. Li X, Pan J, Li H, et al. DsbA-L mediated renal tubulointerstitial fibrosis in UUO mice. Nat Commun. 2020;11(1):4467. [published Online First: Epub Date]. 10.1038/s41467-020-18304-z
25. Xu L, Li X, Zhang F, Wu L, Dong Z, Zhang D. EGFR drives the progression of AKI to CKD through HIPK2 overexpression. *Theranostics*. 2019;9(9):2712-2726. [published Online First: Epub Date]. 10.7150/thno.31424

26. Liu Z, Yang D, Gao J, et al. Discovery and validation of miR-452 as an effective biomarker for acute kidney injury in sepsis. *Theranostics*. 2020;10(26):11963-11975. [published Online First: Epub Date]. 10.7150/thno.50093

27. Wu DI, Chen XiangMei, Guo DengFu, et al. Knockdown of fibronectin induces mitochondria-dependent apoptosis in rat mesangial cells. *J Am Soc Nephrol*. 2005;16(3):646-657. [published Online First: Epub Date]. 10.1681/asn.2004060445

28. Lameire NH, Bagga A, Cruz D, et al. Acute kidney injury: an increasing global concern. *Lancet*. 2013;382(9887):170-179. [published Online First: Epub Date]. 10.1016/s0140-6736(13)60647-9

29. Bonegio R, Lieberthal W. Role of apoptosis in the pathogenesis of acute renal failure. *Curr Opin Nephrol Hypertens*. 2002;11(3):301-308. [published Online First: Epub Date]. 10.1097/00041552-200205000-00006

30. Li J, Gui Y, Ren J, et al. Metformin protects against cisplatin-induced tubular cell apoptosis and acute kidney injury via AMPKα-regulated autophagy induction. *Sci Rep*. 2016;6:23975. [published Online First: Epub Date]. 10.1038/srep23975

31. Misuth M, Joniova J, Horvath D, et al. The flashlights on a distinct role of protein kinase Cδ: phosphorylation of regulatory and catalytic domain upon oxidative stress in glioma cells. *Cell Signal*. 2017;34:11-22. [published Online First: Epub Date]. 10.1016/j.cellsig.2017.02.020

32. Tang Y, Sorouh F, Sun S, et al. Protein kinase C-delta inhibition protects blood-brain barrier from sepsis-induced vascular damage. *J Neuroinflammation*. 2018;15(1):309. [published Online First: Epub Date]. 10.1186/s12974-018-1342-y

33. Sorouh F, Tang Y, Guglielmo K, et al. Protein kinase C-Delta (PKCδ) tyrosine phosphorylation is a critical regulator of neutrophil-endothelial cell interaction in inflammation. *Shock*. 2019;51(5):538-547. [published Online First: Epub Date]. 10.1097/shk.0000000000001247

34. Song SJ, Kim S-M, Lee S-H, et al. Rhabdomyolysis-Induced AKI was ameliorated in NLRP3 KO mice via alleviation of mitochondrial lipid peroxidation in renal tubular cells. *Int J Mol Sci*. 2020;21(22):8564. [published Online First: Epub Date]. 10.3390/ijms21228564

35. Maioli E, Daveri E, Maellaro E, I letta F, Cresti L, Valacchi G. Non-conventional rottlerin anticancer properties. *Arch Biochem Biophys*. 2018;645:50-53. [published Online First: Epub Date]. 10.1016/j.abb.2018.03.009

36. Lee TH, Chen JL, Liu PS, Tsai MM, Wang SJ, Hsieh HL. Rottlerin, a natural polyphenol compound, inhibits upregulation of matrix metalloproteinase-9 and brain astrocytic migration by reducing PKC-δ-dependent ROS signal. *J Neuroinflammation*. 2020;17(1):177. [published Online First: Epub Date]. 10.1186/s12974-020-01859-5

37. Xie Y, Liu B, Pan J, et al. MBD2 mediates septic AKI through activation of PKCθ/p38MAPK and the ERK1/2 axis. *Mol Ther Nucleic Acids*. 2021:23:76-88. [published Online First: Epub Date]. 10.1016/j.omtn.2020.09.028

38. Sun Y, Liu WZ, Liu T, Feng X, Yang N, Zhou HF. Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis. *J Recept Signal Transduct Res*. 2015;35(6):600-604. [published Online First: Epub Date]. 10.3109/12974-020-01859-5

39. Alese MO, Moodley J, Naicker TA. Signalling of ERK1/2, P38MAPK and P90RSK in HIV-associated pre-eclampsia. *J Obstet Gynaecol*. 2019;39(5):612-618. [published Online First: Epub Date]. 10.1080/01443615.2018.1547695

40. Cuadrado A, Nebreda AR. Mechanisms and functions of p38 MAPK signalling. *Biochem J*. 2010;429(3):403-417. [published Online First: Epub Date]. 10.1042/bj20100323

41. Borges G, Berrocoso E, Mico JA, Neto F. ERK1/2: function, signaling and implication in pain and pain-related anxiety-depressive disorders. *Prog Neuropsychopharmacol Biol Psychiatry*. 2015;60:77-92. [published Online First: Epub Date]. 10.1016/j.pnpbp.2015.02.010

**SUPPORTING INFORMATION**

Additional supporting information may be found in the online version of the article at the publisher’s website.

**How to cite this article:** Wu D, Pan J, Zhang D. Inhibition of PKCδ reduce rhabdomyolysis-induced acute kidney injury. *J Cell Mol Med*. 2022;26:3243-3253. doi:10.1111/jcmm.17331